NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 273.13 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.02
▼ -0.06 (-1.47%)

This chart shows the closing price for LJPC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New La Jolla Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LJPC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LJPC

Analyst Price Target is $15.00
▲ +273.13% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for La Jolla Pharmaceutical in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 273.13% upside from the last price of $4.02.

This chart shows the closing price for LJPC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in La Jolla Pharmaceutical. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/10/2021Chardan CapitalReiterated RatingBuy$15.00High
6/24/2020Ci CapitalReiterated RatingBuy$8.00High
11/26/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
11/25/2019SunTrust BanksDowngradeBuy ➝ HoldHigh
11/13/2019HC WainwrightLower Price TargetBuy$27.00 ➝ $19.00High
8/29/2019HC WainwrightSet Price TargetBuy$27.00Low
8/15/2019Chardan CapitalReiterated RatingBuyHigh
6/24/2019Chardan CapitalSet Price TargetBuy$20.00Low
6/6/2019HC WainwrightBoost Price TargetBuy ➝ Positive$25.00 ➝ $27.00High
4/24/2019HC WainwrightReiterated RatingBuy$26.00High
3/5/2019CowenReiterated RatingBuyHigh
1/23/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$18.00 ➝ $9.00High
1/18/2019SunTrust BanksLower Price TargetBuy$20.00Medium
1/14/2019Jefferies Financial GroupUpgradeUnderperform ➝ Hold$13.00 ➝ $6.00High
1/9/2019HC WainwrightLower Price TargetBuy$25.00High
10/25/2018HC WainwrightReiterated RatingBuy$48.00High
9/7/2018HC WainwrightReiterated RatingBuy$53.00Medium
8/10/2018JPMorgan Chase & Co.Lower Price TargetUnderweight ➝ Underweight$24.00 ➝ $21.00High
8/9/2018Jefferies Financial GroupLower Price TargetUnderperform ➝ Underperform$23.00 ➝ $22.00High
8/9/2018SunTrust BanksSet Price TargetBuy$45.00High
8/9/2018HC WainwrightReiterated RatingBuy$53.00High
7/27/2018HC WainwrightLower Price TargetBuy$53.00High
6/18/2018Chardan CapitalReiterated RatingBuy$115.00Low
5/11/2018HC WainwrightReiterated RatingBuy$72.00 ➝ $83.00High
3/22/2018HC WainwrightLower Price TargetBuy$83.00Low
2/12/2018Jefferies Financial GroupDowngradeBuy ➝ Underperform$40.00 ➝ $29.00High
1/25/2018Chardan CapitalBoost Price TargetNeutral ➝ Buy$90.00 ➝ $100.00High
12/29/2017HC WainwrightBoost Price TargetBuy$62.00 ➝ $91.00Low
12/28/2017SunTrust BanksSet Price TargetBuy$57.00 ➝ $65.00Low
12/22/2017CowenReiterated RatingBuy$55.00Medium
12/22/2017Chardan CapitalReiterated RatingBuy$90.00Medium
12/22/2017JPMorgan Chase & Co.Reiterated RatingSellHigh
12/22/2017SunTrust BanksReiterated RatingBuy ➝ Buy$67.00 ➝ $65.00Low
12/21/2017HC WainwrightInitiated CoverageBuy ➝ Buy$62.00 ➝ $62.00High
12/8/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$20.00High
10/27/2017CowenReiterated RatingBuy$55.00N/A
10/3/2017Jefferies Financial GroupReiterated RatingBuy$40.00Low
8/30/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$36.00Low
8/8/2017Chardan CapitalReiterated RatingBuy$85.00Low
7/25/2017Jefferies Financial GroupReiterated RatingBuy$40.00Low
5/22/2017Chardan CapitalSet Price TargetBuy$34.00Low
5/22/2017SunTrust BanksReiterated RatingBuy$57.00Medium
4/30/2017Noble FinancialReiterated RatingBuyLow
4/28/2017CowenReiterated RatingBuy$55.00Low
4/22/2017SunTrust BanksReiterated RatingBuy$57.00Low
3/29/2017Jefferies Financial GroupReiterated RatingBuy$40.00Low
3/2/2017Chardan CapitalBoost Price TargetBuy$80.00 ➝ $90.00N/A
2/28/2017CowenReiterated RatingOutperform$40.00 ➝ $55.00N/A
2/28/2017JPMorgan Chase & Co.Reiterated RatingBuy$27.00 ➝ $40.00N/A
2/27/2017SunTrust BanksReiterated RatingBuy ➝ Buy$38.00 ➝ $57.00N/A
1/24/2017Chardan CapitalReiterated RatingTop Pick$75.00N/A
1/23/2017Jefferies Financial GroupReiterated RatingBuy$27.00N/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
La Jolla Pharmaceutical logo
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $4.02
Low: $4.00
High: $4.39

50 Day Range

MA: $3.94
Low: $3.54
High: $4.37

52 Week Range

Now: $4.02
Low: $3.35
High: $7.85

Volume

315,646 shs

Average Volume

482,450 shs

Market Capitalization

$110.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.36

Frequently Asked Questions

What sell-side analysts currently cover shares of La Jolla Pharmaceutical?

The following Wall Street research analysts have issued stock ratings on La Jolla Pharmaceutical in the last twelve months: Chardan Capital, and Zacks Investment Research.
View the latest analyst ratings for LJPC.

What is the current price target for La Jolla Pharmaceutical?

1 Wall Street analysts have set twelve-month price targets for La Jolla Pharmaceutical in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 273.1%. Chardan Capital has the highest price target set, predicting LJPC will reach $15.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $15.00 for La Jolla Pharmaceutical in the next year.
View the latest price targets for LJPC.

What is the current consensus analyst rating for La Jolla Pharmaceutical?

La Jolla Pharmaceutical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LJPC will outperform the market and that investors should add to their positions of La Jolla Pharmaceutical.
View the latest ratings for LJPC.

What other companies compete with La Jolla Pharmaceutical?

How do I contact La Jolla Pharmaceutical's investor relations team?

La Jolla Pharmaceutical's physical mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company's listed phone number is (617) 715-3600 and its investor relations email address is [email protected] The official website for La Jolla Pharmaceutical is www.lajollapharmaceutical.com.